Astrocyte Pharmaceuticals Announces FDA Clearance of its Investigational New Drug Application for AST-004
March 12, 2024 12:00 ET
|
Astrocyte Pharmaceuticals
Astrocyte Pharmaceuticals Announces FDA Clearance of its Investigational New Drug Application for AST-004
Moleac’s NeuroAiD™II Improves Post-Concussion Symptoms, Quality of Life, and Mood after a Mild Traumatic Brain Injury
December 04, 2023 22:41 ET
|
Moleac Pte Ltd
Promising results from the SAMURAI study show NeuroAiDTMII significantly improves post-concussion symptoms, QoL and mood post-mild traumatic brain injury.
Incannex Healthcare Announces Completion of its Redomiciliation to the United States
November 29, 2023 13:40 ET
|
Incannex Healthcare
MELBOURNE, Australia and NEW YORK, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ: IXHL) is pleased to announce that its previously announced transaction to redomicile Incannex...
Federal Court of Australia Approves Incannex’s Re-Domiciliation and Lodgement of Court Orders With ASIC
November 16, 2023 08:30 ET
|
Incannex Healthcare
MELBOURNE, Australia, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (ASX: IHL) (NASDAQ: IXHL) (the “Company” or “Incannex”) is pleased to announce that the Federal Court of Australia...
Post-acute Care Market Worth $1.37 Billion, Globally, Billion by 2030 - Exclusive Report by The Insight Partners
October 26, 2023 07:36 ET
|
The Insight Partners
Pune, India, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Post-acute care encompasses a broad range of services the patient gets after hospitalization. Sometimes, these services are provided as an alternative...
Aviv Clinics Highlights New Literature Review Sharing the Efficacy of Hyperbaric Oxygen Therapy for Traumatic Brain Injury Patients
August 01, 2023 13:24 ET
|
Aviv Clinics
ORLANDO, Fla., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Aviv Clinics, one of the most advanced brain clinics in the world, shares the results of a new comprehensive literature review that shows hyperbaric...
Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies
June 05, 2023 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, June 05, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage...
Neuronic and Santa Clara University partner to develop next-gen neurotech for photobiomodulation guided by real-time brain activity
May 11, 2023 12:00 ET
|
Neuronic Devices Operations GmbH
Integrating photobiomodulation with neurofeedback will revolutionize treatment of brain disorders SANTA CLARA, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Neuronic, a multi-national company focused...
Algernon NeuroScience Announces U.S. SEC Qualification of Regulation A+ Tier II Offering to Raise up to USD $10M
April 03, 2023 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, April 03, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage...
Telesis Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Guidance
March 21, 2023 16:05 ET
|
Telesis Bio
-- Record revenue of $9.5M in 4QFY22; Increase of 208% over 4QFY21 -- BioXp® Revenue increased by 158% to $3.4M, in 4QFY22 over 4QFY21 SAN DIEGO, March 21, 2023 (GLOBE NEWSWIRE) -- Telesis Bio...